By otakuyassine3@gmail.com 
M. Kraus & Co cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 0.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,213 shares of the medical research company’s stock after selling 53 shares during the quarter. Thermo Fisher Scientific makes up about 4.9% of M. Kraus & Co’s portfolio, making the stock its 4th largest position. M. Kraus & Co’s holdings in Thermo Fisher Scientific were worth $16,238,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. grew its stake in shares of Thermo Fisher Scientific by 74.7% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 166 shares of the medical research company’s stock worth $86,000 after acquiring an additional 71 shares in the last quarter. Rockland Trust Co. grew its position in Thermo Fisher Scientific by 5.7% in the 4th quarter. Rockland Trust Co. now owns 32,059 shares of the medical research company’s stock worth $16,678,000 after purchasing an additional 1,721 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its stake in Thermo Fisher Scientific by 78.7% in the 4th quarter. Fifth Third Wealth Advisors LLC now owns 6,964 shares of the medical research company’s stock valued at $3,623,000 after buying an additional 3,067 shares during the last quarter. CCLA Investment Management grew its stake in Thermo Fisher Scientific by 3.6% in the 4th quarter. CCLA Investment Management now owns 258,571 shares of the medical research company’s stock valued at $134,498,000 after purchasing an additional 8,985 shares during the period. Finally, Community Trust & Investment Co. raised its stake in shares of Thermo Fisher Scientific by 2.2% during the 4th quarter. Community Trust & Investment Co. now owns 33,388 shares of the medical research company’s stock worth $17,369,000 after purchasing an additional 714 shares during the period. 89.23% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the company. JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Stephens assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price target for the company. Bernstein Bank lifted their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Finally, Redburn Atlantic started coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $648.95.
Check Out Our Latest Analysis on Thermo Fisher Scientific
Thermo Fisher Scientific Price Performance
Shares of Thermo Fisher Scientific stock opened at $557.49 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The stock has a market capitalization of $213.24 billion, a P/E ratio of 34.95, a price-to-earnings-growth ratio of 3.54 and a beta of 0.76. The business’s 50 day simple moving average is $529.85 and its two-hundred day simple moving average is $568.13.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the prior year, the firm posted $5.69 earnings per share. The company’s quarterly revenue was up .2% compared to the same quarter last year. Analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s payout ratio is currently 9.78%.
Thermo Fisher Scientific announced that its Board of Directors has approved a stock buyback plan on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board believes its stock is undervalued.
Insider Activity
In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at $67,175,513.68. The trade was a 7.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares of the company’s stock, valued at $7,134,197.76. The trade was a 13.57 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,150 shares of company stock valued at $25,954,465. Corporate insiders own 0.34% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Recommended Stories
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.